EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Allogene Therapeutics, Inc. (ALLO) EBITDA Margin data is not available.
| Income Statement Financials | |
-- |
|
$-41.40M |
|
-- |
|
-- |
|
$44.90M |
|
$-44.90M |
|
$3.50M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-44.90M |
|
$-42.73M |
|
222.04M |
|
222.04M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$260.72M |
|
$75.90M |
|
$179.05M |
|
$439.77M |
|
$31.83M |
|
-- |
|
$92.61M |
|
$124.44M |
|
$315.33M |
|
$315.33M |
|
$315.33M |
|
223.16M |
|
| Cash Flow Statement Financials | |
$-121.65M |
|
$61.95M |
|
$22.30M |
|
$85.51M |
|
$48.11M |
|
$-37.40M |
|
$29.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
EBITDA Margin |
-- |
-- |
|
-- |
|
$-122.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.13% |
|
-13.13% |
|
-9.41% |
|
-13.13% |
|
$1.41 |
|
$-0.55 |
|
$-0.55 |
|